EUVIMEDEUVIMED entdecken
Crossref

Efficacy of Nitazoxanide in reducing the viral ad in COVID-19 patients. Randomized, placebo-controlled, single-blinded, parallel-group, pilot study.

Marcelo Silva, Andrés Espejo, María L Pereyra, Martín Lynch, Marcos Thompson, Luciana Laborde, Hernán Taconelli, Patricia Patricia, Matías J Pereson, Marcelo Garbini, Pablo Crucci, Diego Enriquez

Medical Research Archives · 28.02.2023 · 11 (2)

DOI: 10.18103/mra.v11i2.3364 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medical Research Archives, online erschienen am 28.02.2023. Verfasst von Marcelo Silva und 11 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The fast spread of COVID-19 has overcrowded Public Health Systems facilities in major countries due to the large number of seriously ill patients, particularly those requiring admission to intensive care units. Reducing viral load, along with other recommended epidemiological measures, such as social distancing and home confinement, can in time significantly help to reduce the infection R0 (Basic Reproductive Rate) and then mitigate disease burden. Early negativization or otherwise reduction of the viral load can potentially diminish disease severity, resulting in a better-controlled public health response, avoiding collapse of healthcare systems. Nitazoxanide, a widely used thiazolide approved by the FDA as an antiparasitic drug, also approved in Brazil for Norovirus and Rotavirus treatments, has an excellent safety record for a variety of indications. Nitazoxanide exhibits activity in vitro against MERS-CoV and other coronaviruses; and a specific antiviral effect (in micro molar doses) against SARS-CoV-2. The objective of this study was to evaluate the efficacy and safety of Nitazoxanide in reducing the SARS-COV 2 viral load within 7 days of treatment in respiratory samples from COVID-19-infected patients with mild to moderate disease, compared to placebo. An interim analysis showed that the ratio of patients with a viral load reduction ≥ 35% from baseline up to day 7 of treatment was significantly greater for Nitazoxanide compared to placebo (47.8% vs. 15.4%; Δ 34.6%; 95% CI: 64.7; 4.6: p = 0.037).

Zitieren

APA

Silva, M., Espejo, A., Pereyra, M. L., Lynch, M., Thompson, M., Laborde, L., Taconelli, H., Patricia, P., Pereson, M. J., Garbini, M., Crucci, P., & Enriquez, D. (2023). Efficacy of Nitazoxanide in reducing the viral ad in COVID-19 patients. Randomized, placebo-controlled, single-blinded, parallel-group, pilot study. Medical Research Archives, 11(2). https://doi.org/10.18103/mra.v11i2.3364

Vancouver

Silva M, Espejo A, Pereyra ML, Lynch M, Thompson M, Laborde L, et al. Efficacy of Nitazoxanide in reducing the viral ad in COVID-19 patients. Randomized, placebo-controlled, single-blinded, parallel-group, pilot study. Medical Research Archives. 2023;11(2). doi:10.18103/mra.v11i2.3364

BibTeX
@article{Silva2023,
  author = {Silva, Marcelo and Espejo, Andrés and Pereyra, María L and Lynch, Martín and Thompson, Marcos and Laborde, Luciana and Taconelli, Hernán and Patricia, Patricia and Pereson, Matías J and Garbini, Marcelo and Crucci, Pablo and Enriquez, Diego},
  title = {Efficacy of Nitazoxanide in reducing the viral ad in COVID-19 patients. Randomized, placebo-controlled, single-blinded, parallel-group, pilot study},
  journal = {Medical Research Archives},
  year = {2023},
  volume = {11},
  number = {2},
  doi = {10.18103/mra.v11i2.3364}
}
Kostenlos starten →